Literature DB >> 21704348

Overexpression of hepatic 5α-reductase and 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients.

René Baudrand1, José Miguel Domínguez, Cristian A Carvajal, Arnoldo Riquelme, Carmen Campino, Stefano Macchiavello, Milan Bozinovic, Mauricio Morales, Margarita Pizarro, Nancy Solis, Alex Escalona, Camilo Boza, Marco Arrese, Carlos E Fardella.   

Abstract

11-β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts cortisone to cortisol, mainly in the liver and visceral adipose tissue (VAT), and has been implicated in several metabolic disorders. The absence of systemic hypercortisolism in central obesity could be due to increased inactivation of cortisol to its tetrahydrometabolites by the hepatic enzymes 5α- and 5β-reductases. Our aim was to assess the expression of the reductases in the liver and of 11β-HSD1 in the liver and VAT in morbidly obese patients and to analyze their association with clinical, anthropometric, and biochemical parameters. Hepatic and VAT samples were obtained during bariatric surgery. 5α- and 5β-reductases, 11β-HSD1, and 18S expression was measured using real-time polymerase chain reaction. Anthropometric and biochemical variables were analyzed. Forty-one patients were recruited (age, 41.8 ± 10.6 years; body mass index, 42.1 ± 6.6 kg/m(2); 71% women). The expression of hepatic 5α- and 5β-reductases was positively correlated (r = +0.53, P = .004), and their expression levels were correlated with hepatic 11β-HSD1 expression (r = +0.61, P < .001 for 5α-reductase and r = +0.50, P < .001 for 5β-reductase). Hepatic 5α-reductase was associated with insulin (r = +0.34, P = .015). Visceral adipose tissue 11β-HSD1 expression was associated with glucose (r = +0.37, P = .025) and insulin (r = +0.54, P = .002). Our results showed that 5α-reductase and VAT 11β-HSD1 expressions were associated with insulinemia. These findings suggest that overexpression of 5α-reductase, through a higher inactivation of cortisol in the liver, could have a protective role in preserving hepatic sensitivity to insulin. The overexpression of liver reductases in obesity could be an adaptive response to an increase in cortisol production by the liver and visceral 11β-HSD1 to avoid systemic hypercortisolism.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704348     DOI: 10.1016/j.metabol.2011.05.001

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

Review 1.  Cortisol dysregulation in obesity-related metabolic disorders.

Authors:  Rene Baudrand; Anand Vaidya
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

2.  Ectopic lipid deposition mediates insulin resistance in adipose specific 11β-hydroxysteroid dehydrogenase type 1 transgenic mice.

Authors:  Abudukadier Abulizi; João-Paulo Camporez; Dongyan Zhang; Varman T Samuel; Gerald I Shulman; Daniel F Vatner
Journal:  Metabolism       Date:  2018-12-19       Impact factor: 8.694

3.  Neonatal overfeeding causes higher adrenal catecholamine content and basal secretion and liver dysfunction in adult rats.

Authors:  E P S Conceição; E G Moura; I H Trevenzoli; N Peixoto-Silva; C R Pinheiro; V Younes-Rapozo; E Oliveira; P C Lisboa
Journal:  Eur J Nutr       Date:  2012-09-29       Impact factor: 5.614

4.  Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet.

Authors:  Guoping Li; Antonio Hernandez-Ono; Rosanne M Crooke; Mark J Graham; Henry N Ginsberg
Journal:  Metabolism       Date:  2011-12-29       Impact factor: 8.694

Review 5.  5β-Reduced steroids and human Δ(4)-3-ketosteroid 5β-reductase (AKR1D1).

Authors:  Mo Chen; Trevor M Penning
Journal:  Steroids       Date:  2014-02-08       Impact factor: 2.668

6.  Specific reduction of G6PT may contribute to downregulation of hepatic 11β-HSD1 in diabetic mice.

Authors:  Hanze Du; Limei Liu; Ying Wang; Yuichi Nakagawa; Alexei Lyzlov; Kabirullah Lutfy; Theodore C Friedman; Xiaozhong Peng; Yanjun Liu
Journal:  J Mol Endocrinol       Date:  2013-02-15       Impact factor: 5.098

Review 7.  Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease.

Authors:  Giovanni Tarantino; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

8.  Association of HSD11B1 polymorphic variants and adipose tissue gene expression with metabolic syndrome, obesity and type 2 diabetes mellitus: a systematic review.

Authors:  Filipe Valvassori do Nascimento; Vanessa Piccoli; Mayara Abichequer Beer; Anize Delfino von Frankenberg; Daisy Crispim; Fernando Gerchman
Journal:  Diabetol Metab Syndr       Date:  2015-04-28       Impact factor: 3.320

9.  Curcumin as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats.

Authors:  Guo-Xin Hu; Han Lin; Qing-Quan Lian; Shu-Hua Zhou; Jingjing Guo; Hong-Yu Zhou; Yanhui Chu; Ren-Shan Ge
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

10.  Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice.

Authors:  Joanna K Dowman; Laurence J Hopkins; Gary M Reynolds; Matthew J Armstrong; Maryam Nasiri; Nikolaos Nikolaou; E Leonie A F van Houten; Jenny A Visser; Stuart A Morgan; Gareth G Lavery; Andrei Oprescu; Stefan G Hübscher; Philip N Newsome; Jeremy W Tomlinson
Journal:  Endocrinology       Date:  2013-09-30       Impact factor: 4.736

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.